AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

AngioDynamics, Inc. (NASDAQ:ANGO) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $18.6667.

Several analysts have recently commented on ANGO shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Zacks Research downgraded shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. Finally, Canaccord Genuity Group lowered their target price on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a report on Monday, April 6th.

Institutional Trading of AngioDynamics

Several institutional investors and hedge funds have recently made changes to their positions in ANGO. Farther Finance Advisors LLC increased its holdings in AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 1,199 shares during the last quarter. Washington Trust Advisors Inc. purchased a new stake in AngioDynamics during the third quarter worth about $27,000. Kemnay Advisory Services Inc. purchased a new stake in AngioDynamics during the fourth quarter worth about $27,000. State of Wyoming purchased a new stake in AngioDynamics during the second quarter worth about $31,000. Finally, Russell Investments Group Ltd. increased its holdings in AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 3,213 shares during the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Trading Up 1.4%

ANGO opened at $12.15 on Friday. The company’s fifty day moving average price is $11.17 and its two-hundred day moving average price is $11.38. The company has a market cap of $502.04 million, a price-to-earnings ratio of -16.20 and a beta of 0.38. AngioDynamics has a 1-year low of $8.36 and a 1-year high of $13.99.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.04. The company had revenue of $78.42 million during the quarter, compared to the consensus estimate of $76.77 million. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. As a group, equities analysts forecast that AngioDynamics will post -0.19 earnings per share for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.